



## **Edimer Adds Biotech Veteran Dan Lynch to Board**

### *Company Accesses Finance, Deal-making, and Clinical Development Expertise in Advance of Pending Milestone Events*

Cambridge, Mass. – July 28, 2011 – Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the appointment of Daniel Lynch to the company's board of directors.

“As Edimer approaches our first clinical trials over the next year, we are excited that Dan will bring to the team industry-leading expertise and a passion for drug development to help in this important effort,” said Neil Kirby, Ph.D., President and CEO of Edimer. “Orphan and pediatric indications are among the most challenging from a development, regulatory and clinical perspective. Dan will serve as a great resource on our Board as we continue the work towards achieving Edimer’s vision of significantly improving the lives of future generations of patients living with XLHED.”

“Edimer is poised to do something unprecedented – permanently correct a genetic disorder via treatment with a drug,” said Mr. Lynch. “It is an exciting opportunity to be part of this game-changing endeavor focused on treating a serious orphan disease and I look forward to collaborating with the Edimer team and fellow Board members to help reach the potential for EDI200.”

Mr. Lynch brings more than 25 years of experience serving in management positions in the biotechnology and pharmaceutical industries. He recently joined Third Rock Ventures in 2011 as an Entrepreneur-in-Residence. He is currently executive chairman of the board for two companies – Avila Therapeutics, Inc. ([www.avilatx.com](http://www.avilatx.com)) and Stromedix, Inc. ([www.stromedix.com](http://www.stromedix.com)) – and a member of the board of directors for bluebird bio ([www.bluebirdbio.com](http://www.bluebirdbio.com)). Dan spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, he led ImClone through a significant turnaround, helping to restore the company's reputation and to secure FDA approval of ERBITUX® (Cetuximab), a novel cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He previously served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December, 2010, when it was acquired by McKesson. Dan received his B.A. in mathematics from Wesleyan University and his M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.

## **About XLHED**

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) is a rare genetic disorder diagnosed on the basis of fine, sparse hair (hypotrichosis); few and often pointed teeth (hypodontia); diminished or absent sweat function (hypohidrosis); and recurrent respiratory infections in infancy. XLHED is associated with mutations in the EDA gene and is the most common of over 170 different ectodermal dysplasias. XLHED affects primarily males and, in its most severe form, is associated with serious and potentially life-threatening illness in infancy resulting from a lack of sweating leading to hyperthermia and from respiratory infections. Through childhood, the focus of medical care for XLHED patients shifts to the chronic skin issues and severe hypodontia with its associated medical and self-esteem issues. Dentures may be prescribed as early as age 2-3 years to enhance feeding, growth, and speech and to begin to address what are often life-long psychosocial issues. As an X-linked genetic disorder, males with their single X-chromosome are fully affected by XLHED, while females inheriting one normal and one altered X-chromosome are variably affected. XLHED has received orphan designation in both the EU and the U.S.

## **About Edimer Pharmaceuticals**

Edimer is a privately held biotechnology company based in Cambridge, Massachusetts dedicated to delivering a significant and durable improvement in the health and quality of life to future generations affected by XLHED. Edimer's lead product candidate, EDI200, is an EDA replacement protein representing the first of a new class of molecules designed to permanently correct a developmental disorder. Edimer was established in 2009 with an investment from Third Rock Ventures and VI Partners.

For further information on Edimer Pharmaceuticals, please visit [www.edimerpharma.com](http://www.edimerpharma.com). To receive quarterly updates about Edimer Pharmaceuticals' progress please join the XLHED network at [www.xlhednetwork.com](http://www.xlhednetwork.com).

## **CONTACTS:**

### **Edimer Pharmaceuticals**

Jeff Behrens, 617-758-4300  
Senior Director, Business Development and Operations

Maureen L. Suda (Media)  
Suda Communications LLC  
585-387-0818

###